Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

To attract and retain workers, employers will focus on competitive salaries and flexible benefits, experts say.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

Sharon Mann has lost nearly 30 pounds since starting on Mounjaro, a GLP-1 medication. Dr. Sanjay Gupta reports.

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

UK investment bank Peel Hunt suggests food inflation could near 4% by the end of 2025 as supermarkets react to cost pressures arising from Labour’s budget in October.

Highmark Health President and CEO David Holmberg discussed the uncertainties facing the insurance industry, including the ...